Oramorph (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Oramorph, is an opioid analgesic presented as a strength/form for oral use. It treats moderate to severe pain, particularly when other analgesics are insufficient, and is used in adult and pediatric patients under strict medical supervision.

GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oramorph is an opioid analgesic that acts on the central nervous system to relieve pain in several clinical contexts. - Acute postoperative pain: Provides strong analgesia during the immediate recovery period after surgery. - Cancer‑related pain: Helps manage persistent pain associated with malignant disease. - Severe chronic non‑cancer pain: Used when pain is intense and other treatments have failed.

Adverse reactions to morphine can vary in frequency and severity.

Common Side Effects: - Constipation: Reduced gastrointestinal motility leading to hard stools. - Nausea and vomiting: Stimulation of the chemoreceptor trigger zone. - Drowsiness: Central nervous system depression. - Dry mouth: Decreased salivary secretion. - Pruritus: Histamine release causing itching. - Urinary retention: Decreased bladder contractility.

Serious or Rare Side Effects: - Respiratory depression: Reduced drive to breathe, potentially life‑threatening. - Severe hypotension: Marked drop in blood pressure. - Opioid dependence or addiction: Development of physical or psychological reliance. - Anaphylaxis: Rare severe allergic reaction. - adrenal insufficiency: Suppression of the hypothalamic‑pituitary‑adrenal axis. - Myoclonus: Involuntary muscle jerks, especially at high doses.

When prescribing Oramorph, clinicians should evaluate patient‑specific factors and monitor for adverse events. - Assess renal and hepatic function: Adjust dosing in impairment. - Evaluate respiratory status: Avoid use in patients with severe respiratory compromise. - Review concomitant CNS depressants: Increased risk of sedation and respiratory depression. - Monitor for signs of dependence: Counsel patients on safe use. - Pregnancy and lactation: Use only if benefits outweigh risks. - Store at below 25°C: Keep in the original container, protect from moisture and light.

Morphine interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Benzodiazepines: Combined CNS depression can cause profound respiratory depression. - Barbiturates: Potentiates sedative effects and increases overdose risk. - MAO inhibitors: May precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticholinergics: May worsen constipation. - Loop diuretics: Can enhance hypotensive effects. - Selective serotonin reuptake inhibitors (SSRIs): May increase risk of serotonin syndrome. - Antihistamines: May add to sedative load. - Alcohol: Potentiates CNS depression.